Evidence map›Paper›PMID 40410608›Full record

ArticleMolecular and cellular biochemistry2025

CD44 and SLC1A2 are commonly regulated but do not form a fusion transcript in ER+ breast cancer.

Francesca Bonechi, Marina Bacci, Nicla Lorito, Alfredo Smiriglia, Edoardo Pagliantini, Matteo Benelli, Icro Meattini, Andrea Morandi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francesca BonechiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134, Florence, Italy.
Marina BacciDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134, Florence, Italy. marina.bacci@unifi.it.
Nicla LoritoDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134, Florence, Italy.
Alfredo SmirigliaDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134, Florence, Italy.
Edoardo PagliantiniDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134, Florence, Italy.
Matteo BenelliDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134, Florence, Italy.
Icro MeattiniDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134, Florence, Italy.
Andrea MorandiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134, Florence, Italy. andrea.morandi@unifi.it.

Funding

Fondazione AIRC per la ricerca sul cancro ETS 22941
6 · The paper itself

Abstract

Endocrine therapy (ET) is essential for managing ER+ HER2- breast cancer; however, resistance remains a significant clinical challenge. This study investigated whether CD44-SLC1A2 gene fusions, reported in gastrointestinal malignancies, contribute to ET resistance mechanisms in breast cancer. Although no CD44-SLC1A2 fusions were detected, high expression of CD44 and SLC1A2 was associated with poor survival outcomes and identified a therapy-resistant subpopulation sustained by aspartate and glutamate metabolism, highlighting potential metabolic vulnerabilities for future therapeutic intervention.

Indexed as

Breast NeoplasmsGene Expression Regulation, NeoplasticHyaluronan ReceptorsOncogene Proteins, FusionReceptors, EstrogenSodium-Glucose Transporter 1Excitatory Amino Acid Transporter 2FemaleHumansCD44 protein, humanExcitatory Amino Acid Transporter 2Hyaluronan ReceptorsOncogene Proteins, FusionReceptors, EstrogenSLC1A2 protein, humanSodium-Glucose Transporter 1Breast cancerEndocrine therapyMetabolic reprogramming

Identifiers

PMID40410608
PMCPMC12476316

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.